Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 4/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 12/20 | 0.58 |
| ▸ | EGFR | P00533 | 5/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.58 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2189831 | 0.92 | AURKB (0.71) | AURKBAURKAKDREGFRMAPK14 | |
| SCHEMBL2190472 | 0.90 | NPC1 (0.61) | AURKBAURKAKDREGFRMAPK14 | |
| SCHEMBL3947988 | 0.85 | AURKB (0.71) | AURKBAURKAKDREGFRMAPK14 | |
| SCHEMBL2190156 | 0.85 | AURKB (0.71) | AURKBAURKAKDREGFRMAPK14 | |
| SCHEMBL3949424 | 0.84 | KDR (0.61) | AURKBAURKAKDREGFRMAPK14 | |
| SCHEMBL3949732 | 0.84 | KDR (0.72) | AURKBAURKAKDREGFRMAPK14 | |
| SCHEMBL3949004 | 0.84 | KDR (0.73) | AURKBAURKAKDREGFRMAPK14 | |
| SCHEMBL3949215 | 0.83 | KDR (0.60) | AURKBAURKAKDREGFRMAPK14 | |
| SCHEMBL3953290 | 0.82 | KDR (0.60) | AURKBAURKAKDREGFRMAPK14 | |
| SCHEMBL2190460 | 0.81 | EGFR (0.78) | AURKBAURKAKDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172241-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110172241-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20090270410-A1 | BENZAZOLE ANALOGUES AND USES THEREOF | 4SC AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270410-A1 | BENZAZOLE ANALOGUES AND USES THEREOF | 4SC AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270410-A1 | BENZAZOLE ANALOGUES AND USES THEREOF | 4SC AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-7576090-B2 | e.g. N-[2-(6,7-Dimethoxyquinazolin-4-ylamino)benzothiazol-6-yl ]benzamide; multi-target protein kinase, especially epidermal and endothrlial growth factor, inhibitors; antiproliferative, anticarcinogenic agent | 4SC AG (DE) | 2009-08-18 | — | — | US | disclosed |
| US-7576090-B2 | e.g. N-[2-(6,7-Dimethoxyquinazolin-4-ylamino)benzothiazol-6-yl ]benzamide; multi-target protein kinase, especially epidermal and endothrlial growth factor, inhibitors; antiproliferative, anticarcinogenic agent | 4SC AG (DE) | 2009-08-18 | — | — | US | disclosed |
| US-7576090-B2 | e.g. N-[2-(6,7-Dimethoxyquinazolin-4-ylamino)benzothiazol-6-yl ]benzamide; multi-target protein kinase, especially epidermal and endothrlial growth factor, inhibitors; antiproliferative, anticarcinogenic agent | 4SC AG (DE) | 2009-08-18 | — | — | US | disclosed |
| EP-1833823-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE ANALOGUES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006069740-A1 | 2, 5 AND 2, 6-DISUBSTITUTED BENZAZOLE ANALOGUES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2006-07-06 | — | — | WO | disclosed |
| US-20060142570-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2006-06-29 | — | — | US | disclosed |
| EP-1674466-A1 | 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors | 4SC AG (DE) | 2006-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142570-A1 | Benzazole analogues and uses thereof | CYP3A5, CYP3A7, CYP3A43 | AURKB 1348/4885AURKA 1705/4885KDR 4179/4885 |
| US-20110172241-A1 | Benzazole analogues and uses thereof | CYP3A5, CYP3A7, CYP3A43 | AURKB 1348/4885AURKA 1705/4885KDR 4179/4885 |
| US-20090270410-A1 | BENZAZOLE ANALOGUES AND USES THEREOF | CYP3A5, CYP3A7, CYP3A43 | AURKB 1372/4885AURKA 1801/4885KDR 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.